Konjac-mannan and American ginsing: Emerging alternative therapies for type 2 diabetes mellitus

被引:97
作者
Vuksan, V
Sievenpiper, JL
Xu, Z
Wong, EYY
Jenkins, AL
Beljan-Zdravkovic, U
Leiter, LA
Josse, RG
Stavro, MP
机构
[1] St Michaels Hosp, Clin Nutr & Risk Factor Modificat Ctr, Toronto, ON, Canada
[2] Univ Toronto, Fac Med, Dept Nutr Sci, Toronto, ON, Canada
[3] St Michaels Hosp, Div Endocrinol & Metab, Toronto, ON, Canada
关键词
type 2 diabetes mellitus; konjac-mannan; American ginseng;
D O I
10.1080/07315724.2001.10719170
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Despite significant achievements in treatment modalities and preventive measures, the prevalence of diabetes has risen exponentially in the last decade. Because of these limitations there is a continued need for new and more effective therapies. An increasing number of people are using dietary and herbal supplements, even though there is a general lack of evidence for their safety and efficacy. Consequently, science based medical and government regulators are calling for more randomized clinical studies to provide evidence of efficacy and safety. Our research group has selected two such promising and functionally complementary therapies for further investigation as potentially emerging alternative therapies for type 2 diabetes: Konjac-mannan (KJM) and American ginseng (AG). We have generated a mounting body of evidence to support the claim that rheologically-selected, highly-viscous KJM, and AG with a specific composition may be useful in improving diabetes control. reducing associated risk factors such as hyperlipidemia and hypertension, and ameliorating insulin resistance. KJM has a demonstrated ability to modulate the rate of absorption of nutrients from the small bowel. whereas AG has post-absorptive effects. Consequently, it appears that KJM and AG are acting through different. yet complementary, mechanisms: KJM by increasing insulin sensitivity and AG likely by enhancing insulin secretion. Before the therapeutic potential of KJM and AG as novel prandial agents for treatment of diabetes can be fully realized, further controlled trials with larger sample sizes and of longer duration are required. A determination of the active ingredients in AG, and the theology-biology relationship of KJM are also warranted.
引用
收藏
页码:370S / 380S
页数:11
相关论文
共 61 条
[1]  
AKAZAWA Y, 1981, AGR BIOL CHEM TOKYO, V45, P323
[2]  
Amer Diabet Assoc, 2000, DIABETES CARE, V23, pS43
[3]  
ANDERSON JW, 1986, AM J GASTROENTEROL, V81, P907
[4]  
[Anonymous], GUMS STABILISERS FOO
[5]   EFFECT OF SHORT-TERM INGESTION OF KONJAC GLUCOMANNAN ON SERUM-CHOLESTEROL IN HEALTHY-MEN [J].
ARVILL, A ;
BODIN, L .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1995, 61 (03) :585-589
[6]   ATHEROGENESIS IN DIABETES [J].
BIERMAN, EL .
ARTERIOSCLEROSIS AND THROMBOSIS, 1992, 12 (06) :647-656
[7]  
Brown L, 1999, AM J CLIN NUTR, V69, P30
[8]   Aspirin therapy in diabetes [J].
不详 .
DIABETES CARE, 1997, 20 (11) :1772-1773
[9]  
DAVID DJA, 1995, DIABETES CARE, V18, P1491
[10]   Eleutherococcus senticosus (Rupr. & Maxim.) Maxim. (Araliaceae) as an adaptogen:: a closer look [J].
Davydov, M ;
Krikorian, AD .
JOURNAL OF ETHNOPHARMACOLOGY, 2000, 72 (03) :345-393